Clinical trial · Interventional
Second Line Breast Cancer Trial
A Double-Blind, Randomized, Multi-Center Trial Comparing the Efficacy and Tolerability of 125 and 250mg of Faslodex (Long Acting ICI 182,780) With 1mg Arimidex (Anastrazole) in Postmenopausal Women With Advanced Breast Cancer.
NCT00635713CI-TRIAL-00002206completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anastrozole | Drug | Anastrozole | ALIAS |
| Fulvestrant | Drug | Fulvestrant | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- Faslodex 125mg and Arimidex 1 mg
- interventionNames
- Drug: Fulvestrant
- Drug: Anastrozole
- type
- EXPERIMENTAL
- label
- 2
- description
- Faslodex 250mg and Arimidex 1mg
- interventionNames
- Drug: Anastrozole
- Drug: Fulvestrant
Primary outcomes (1)
- measure
- time to tumor progression
- timeFrame
- Every 3 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * postmenopausal women with confirmation of breast cancer * objective evidence of recurrence or progression of breast cancer no more than 1 prior hormonal therapy for breast cancer Exclusion Criteria: * presence of life-threatening metastatic visceral disease * previous treatment with FASLODEX, ARIMIDEX or any aromatase inhibitor for breast cancer * more than 1 prior endocrine medical treatment for advanced breast cancer .
References
Publications (0)
Data not yet available
No reference posted for this study.